Table: Randomised, double blind controlled trials of ketoprofen for acute migraine treatment
Reference Patients Design Intervention Outcomes Results (main outcomes) Quality
Kangasniemi and Kaaja 1992 Adults with migraine without aura according to non-IHS criteria, 3 to 10 attacks per month, baseline pain at least moderate severity, n=52 RCT, DB, CO, 6 attacks, DNS use of rescue analgesia 1. Ketoprofen 100 mg rectal suppository 2. Ergotamine 2 mg rectal suppository 3. Placebo Headache severity VAS (0-100), nausea, vomiting, working ability, patient global assessment n=50 patients analysed for 3 consecutive attacks. Number of patients with at least 50% pain relief at 2 hours: Ketoprofen 23/50 (46%) Ergotamine 12/50 (24%) Placebo 12/50 (24%) NNT ketoprofen v placebo 4.6 (2.5 to 26) NSD ergotamine v placebo R=1 DB=2 W=1 Total=4
Karabestos et al 1997 Adults with migraine without aura according to non-IHS criteria, at least 2 attacks per month, study med taken within 2 hours of migraine onset, n=64 RCT, DB, CO, rescue with ketoprofen 100 mg IM if needed during 2 hour study period 1. Ketoprofen 100 mg IM n=34 2. Paracetamol 500 mg IM n=30 Headache severity (1=mild, 2=moderate, 3=severe), headache duration, nausea, vomiting, photophobia, phonophobia, patient global assessment n=64 patients analysed for single dose. Crossover data not presented. Ketoprofen significantly more effective than paracetamol for reduction in pain and nausea. Number of patients reporting complete relief within 40 minutes: Ketoprofen 28/34 (83%) Paracet R=1 DB=1 W=1 Total=3
Abbreviations: IHS=International Headache Society; RCT=randomised controlled trial; DB=double blind; CO=crossover; DNS=did not state; VAS=visual analogue scale; NNT=number-needed-to-treat; NSD=no significant difference; R=randomised; W=withdrawals and dro

Last Updated on 6/12/00
By Andrew Moore